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1. Introduction 
The glucagon binding to hepatocytes results in an 
immediate increase in intracellular cyclic AMP [ 11, 
which is followed by an increase in glycogenolysis 
and gluconeogenesis [2]. It has been suggested that 
glucagon may be involved in the pathogenesis of 
diabetes mellitus [3]. A specific glucagon antagonist 
could prove useful in determining what relationship 
the hormone has with this disease state. Previous 
investigators [4] have provided evidence that ‘(des- 
His’ )-glucagon’, synthesized by the one-step Edman 
procedure is a competitive inhibitor of glucagon 
action on liver plasma membrane adenylate cyclase. 
A highly purified (des-His’ )-glucagon was synthesized 
by the solid state Edman procedure, which insures 
the integrity of the e-amino group, and was shown 
[5] to be a partial agonist. Therefore, the identity of 
the antagonist remains in doubt. In view of the poten- 
tial usefulness of this inhibitor we decided to reinves- 
tigate the reaction of phenylisothiocyanate with 
glucagon. Here we describe the purification and 
identity of the glucagon antagonist synthesized by 
the one-step Edman degradation and report on some 
of its properties which explain the previous differences. 
2. Materials and methods 
2.1, Materials 
Crystalline glucagon was obtained from Elanco Co. 
DEAE A-25 and Sephadex G-10 were purchased from 
Pharmacia Fine Chemicals. ATP, GTP, cyclic AMP, 
Abbreviations: des-His’, des-Histidine; PTC, phenylthio- 
carbomoyl 
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carboxypeptidase A, dithiothreitol, phosphocreatine 
and phosphokinase were obtained from Sigma. 
Aminopeptidase M was from Rohm and Haas. [(Y-~‘P] - 
ATP and cyclic t3H]AMP were purchased from New 
England Nuclear. All other chemicals were reagent 
grade. 
2.2. Synthesis of(des-His’)(NE-phenylthiocarbamoyl)- 
glu cagon 
Glucagon (40 mg) was dissolved in 3 ml pyridine/ 
H*O/triethylamine (70:30:0.01) and adjusted to 
pH 10.4 with triethylamine. Nitrogen was bubbled 
through the solution, then phenylisothiocyanate 
(150 ~1) was added. The mixture was incubated at 
37°C for 2 h, then extracted with benzene until the 
benzene layer was clear. The aqueous layer was taken 
to dryness in vacua. Trifluoroacetic acid (10 ml) 
containing dithiothreitol (3 mg/ml) was added and 
the sample was sealed under nitrogen for 10 min at 
50°C. The sample was again taken to dryness in vacua. 
The resultant product was then chromatographed on a 
Sephadex G-l 0 column (0.8 X 3 1 cm) which was 
eluted with pyridine/HaO (1: 2). After lyopholization, 
the crude product was dissolved in Tris-urea buffer 
(PH 7.7) and chromatographed on DEAE-Sephadex 
by methods similar to those in [6]. The purified title 
compound was isolated and lyophilized to give a 
white powder (25 mg). 
2.3. Amino acid analysis 
The products were analyzed on a Beckman 120 C 
amino acid analyzer following either acid hydrolysis 
by 6 N HCl for 22 h at 110°C or by proteolysis. The 
peptide sample (-1 mg/ml) was incubated with 
aminopeptidase M (l%, w/w) for 24 h at 30°C in 
20 mM NaHC03 followed by carboxypeptidase A 
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(270, w/w) for 24 h. The enzyme-digested sample 
was added directly to the amino acid analyzer. 
2.4. Liver plasma membrane adenylate cyclase assay 
Liver plasma membranes from rat livers were 
prepared by a nlodi~cation of the procedure [7] as in 
181. Except for the addition of GTP (I 0 ,uM) incuba- 
tion conditions were as in [9]. Cyclic AMP was 
determined by the method in [IO]. Protein was 
determined by the Lowry method [l l] using bovine 
albumin as a standard. 
2.5. Absorption measurements 
Ultraviolet and visible absorption measurements 
were made on a Gilford 240 spectrophotometer. 
3. Results 
3.1. Purification and identification of glucagon 
derivatives synthesized by the Edman degradation 
reaction 
Analysis of the products derived from the reaction 
of glucagon with phenylisothiocyanate by DEAE-- 
Sephadex chromatography is shown in fig. 1. Acid 
hydrolysates of the material in peak A (fig.]) yielded 
an amino acid analysis consistent with (des-His’ )- 
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Fig.1. DEAE-Sephadex chromatography of the products 
derived from the reaction of glucagon with phenylisothio- 
cyanate (-_). Tris buffer, 0.01 M, in 7 M urea (pN 7.7) was 
used as eluent soivent with a discontinuous NaCl gradient 
(- - - -). 
Table 1 
Amino acid analysis - basic amino acids 
___._~______. -.- 
Amino acid Glucagon Peak A Enzymatic Peak B 
talc. acid digests enzymatic 
hydrolysis digest 
Tryptophan 1.0 ud” 0.88 0.92 
Lysine 1.0 0.98 0.95 0.02 
Histidine 1.0 0.01 0.01 0.01 
Arginine 2.0 1.97 1.99 1.94 
a Giucagon contains 1 residue of tryptophan which is lost on 
acid hydrolysis 
glucagon (table 1). Enzyme digests of this peptide 
material in peak A yielded the same analysis, show- 
ing that the e-amino group of Lys- 12 was not modi- 
fied. This was as expected since work with DEAE- 
Sephadex A-25 has shown that glucagon was not held 
by the column unless there was a decrease in net positive 
charge, such as neutralization of the e-amino group 
[6]. As expected, amino acid analysis of the material 
in peak B following peptidase treatment revealed the 
loss of lysine (table 1). Acid or base hydrolysis of 
(de&is*) (NE-PTC)-glucagon led to regeneration of 
the lost lysine (not shown). This was as expected 
since in his earliest work Edman reported [ 121 that 
the IV-PTC group of lysine was removed by base 
hydrolysis. It is also known that in acid hydrolysis 
regeneration of free lysine occurs [13]. In this regard, 
the work in [4] relied solely on acid hydrolysates 
for their analysis thus explaining why they detected 
none of the NE-PTC-lysine which quite likely was 
present in their preparation. We further confirmed 
the presence of the pl~enyltl~iocarbo~~ioyl moiety in 
our purified (des-His’ ) (,~~-PTC)-glucagon by absorp- 
tion measurements. The ratio (A,,,/A1sO) was 0.72 
for glucagon and 1.42 for (des-His’ ) (Nf-PTC)- 
glucagon at pH 10.0. This increase in the ratio is the 
result of the PTC moiety which contributes very sub- 
stantially to AZ6e [ 141. The distribution of material 
between peak A and peak B was directly dependent 
on the pH of the pyridine/water solution used in the 
synthesis. Formation of (des-His’ ) (NE~PTC)-glucagon 
(peak B) was favored at the higher pH values, with 
90% of the peptide material being found in 
peak B at pH 10.4. Lowering the pH increases the 
amount of (des-His’)-glucagon (peak A) formed. For 
proper preparation of the antagonist (des-His’ ) 
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(NE-PTC)-glucagon it is critical, therefore, that the 
pH be carefully controlled during the synthesis. 
3.2. Effect of glucagon a~a~~~es 0~2 liver adenylate 
eye fase 
(des-His' )-glucagon (peak A) is a partial agonist, 
stimulating liver adenylate cyclase activity to 56% of 
the maximum level obtained with glucagon alone 
(fig.2). This partial agonism is very similar to that 
reported for (des-His’)-glucagon prepared by the solid- 
phase Edman procedure [S]. On the other hand 
(des-His’ ) (NE-PTC)-ghtcagon had essentially no effect 
on liver adenylate cyclase activity (fig.2). Maximal 
activity observed was 5% at 1 gM, and this probably 
reflects a slight (I -3%) contamination of (des-His’ )- 
glucagon. This was further affirmed by the com- 
petitive inhibitory action of (des-His’) (NE-PTC)- 
glucagon on glucagon stimulation liver adenylate 
cyclase activity (fig.2). (des-His’ ) (IV-PTC)-glucagon 
(1.5 PM) caused a 26-fold increase in the glucagon 
concentration required for 50% activation (K,). 
Assuming the receptor occupancy is directly propor- 
tional to the adenylate cyclase activity in these 
studies, the antagonist, (des-His’) (NE-PTC)-glucagon, 
would have l/t 8th the affinity of glucagon for the 
receptor site. 
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Fig.2. Effect of (des-His’ ) (me-PTC)glucagon on the glucagon 
stimulation of liver adenylate cyclase activity. Assay condi- 
tions are in section 2. The protein content per assay was 
30 pg. The stimulatory effect of glucagon (-o-), (des-His’) 
(NE-PTC)-glucagon (- - - -), (des-His’)-glucagon (X) and 
glucagon containing (des-His’ ) (NE-PTC)-glucagon, 1.5 PM, 
(-•-) on the adenylate cyclase activity is expressed as % 
activation over basal. 0% activation represents the basal 
activity (270 pmol/lO min/mg protein) and 100% is the 
maximum activity observed with glucagon (2200 pmol/ 
10 mm/mg protein). The results are the mean of 3 deter- 
minations each from triplicate experiments. 
4. Discussion 
This report clearly shows that the glucagon antag- 
onist synthesized by the Edman degradation of 
glucagon is (des-His’ ) (NE-PTC)-ghrcagon. However, 
(des-His’ )-glucagon is a partial agonist ([5] fig.2) as 
was reported. These results indicate that introduction 
of the PTC moiety into the e-amino position of 
glucagon is primarily responsible for generating an 
antagonistic form of the hormone. Other studies have 
shown that incorporation of a hydrophobic moiety 
into the e-amino position results in a loss of biological 
activity [9,15,16]. Physical studies on these derivatives 
(6,163 suggest hat their molecular conformation is 
much more complex than the flexible random coil 
form of monomeric glucagon [ 17- 191. Guanidation 
of the lysine position does not result in an inactive 
derivative [20], which suggests that neutralization of 
the e-amino group may be an important factor con- 
tributing to the new conformation. Additional work 
will be needed to further evaluate the importance of 
these various factors and to obtain a better under- 
standing of the conformational properties of these com- 
pounds. In addition, this antagonist may prove useful 
in evaluating the actions of glucagon in in vitro and 
in vivo systems. Work is currently in progress in our 
laboratory in these areas, and in the synthesis of a 
variety of related glucagon analogues. 
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